4.72MMarket Cap-89P/E (TTM)
2.420High2.250Low91.90KVolume2.420Open2.390Pre Close213.13KTurnover4.43%Turnover RatioLossP/E (Static)2.08MShares36.40052wk High-1.80P/B4.71MFloat Cap1.85052wk Low--Dividend TTM2.08MShs Float23999.988Historical High--Div YieldTTM7.13%Amplitude1.850Historical Low2.319Avg Price1Lot Size
Bio-Path Holdings Stock Forum
Bio-Path Holdings, Inc., a biotechnology company listed on NASDAQ under the ticker symbol BPTH, is leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs. On June 14, 2024...
Bio Path Holdings Inc - Got Nasdaq Letter Granting Extension Until September 8 to Demonstrate Compliance With Stockholders' Equity Requirement
Bio-Path Holdings Reveals Interim Results From Phase 2 Study Of Prexigebersen In Combination With Decitabine And Venetoclax For Treatment Of Acute Myeloid Leukemia
Bio-Path Holdings presented interim results from its Phase 2 study of prexigebersen (BP1001) in combination with decitabine and venetoclax for treating acute myeloid leukemia (AML) at the 2024 European Hematology Association Congress.
Dr. Jorge Cortes presented data showing the combinati...
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
No comment yet